Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536
- PMID: 20145140
- DOI: 10.1158/0008-5472.CAN-09-2181
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536
Abstract
In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR/ABL inhibitors may occur during therapy. Therefore, CML research is focusing on novel targets and targeted drugs. Polo-like kinase 1 (Plk1) is a serine/threonine kinase that plays an essential role in mitosis. In this study, we examined the expression of Plk1 in CML cells and its potential role as a therapeutic target. Plk1 was found to be expressed in phosphorylated form in the CML cell line K562 as well as in primary CML cells in all patients tested. Inhibition of BCR/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR/ABL promotes Plk1 generation. Silencing of Plk1 in CML cells by a small interfering RNA approach was followed by cell cycle arrest and apoptosis. Furthermore, the Plk1-targeting drug BI 2536 was found to inhibit proliferation of imatinib-sensitive and imatinib-resistant CML cells, including leukemic cells, carrying the T315 mutation of BCR/ABL with reasonable IC(50) values (1-50 nmol/L). The growth-inhibitory effects of BI 2536 on CML cells were found to be associated with cell cycle arrest and apoptosis. Moreover, BI 2536 was found to synergize with imatinib and nilotinib in producing growth inhibition in CML cells. In conclusion, Plk1 is expressed in CML cells and may represent a novel, interesting target in imatinib-sensitive and imatinib-resistant CML.
Similar articles
-
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.J Exp Clin Cancer Res. 2019 May 23;38(1):216. doi: 10.1186/s13046-019-1197-9. J Exp Clin Cancer Res. 2019. PMID: 31122263 Free PMC article.
-
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Clin Cancer Res. 2013 Jan 15;19(2):404-14. doi: 10.1158/1078-0432.CCR-12-2799. Epub 2012 Nov 30. Clin Cancer Res. 2013. PMID: 23204129 Free PMC article.
-
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Blood Cells Mol Dis. 2014. PMID: 24629639
-
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.Ann Intern Med. 2006 Dec 19;145(12):913-23. doi: 10.7326/0003-4819-145-12-200612190-00008. Ann Intern Med. 2006. PMID: 17179059 Review.
-
[Research advance on molecular genetics of CML blast crisis].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18315935 Review. Chinese.
Cited by
-
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.Haematologica. 2013 Oct;98(10):1539-46. doi: 10.3324/haematol.2013.084434. Epub 2013 Jun 10. Haematologica. 2013. PMID: 23753023 Free PMC article.
-
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14. Br J Cancer. 2012. PMID: 22699824 Free PMC article. Clinical Trial.
-
Antioxidant enzyme peroxiredoxin 5 regulates cyst growth and ciliogenesis via modulating Plk1 stability.FASEB J. 2022 Jan;36(1):e22089. doi: 10.1096/fj.202101270RR. FASEB J. 2022. PMID: 34888938 Free PMC article.
-
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.PLoS One. 2013 Oct 14;8(10):e77390. doi: 10.1371/journal.pone.0077390. eCollection 2013. PLoS One. 2013. PMID: 24155950 Free PMC article.
-
Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.Oncogene. 2011 Nov 17;30(46):4666-77. doi: 10.1038/onc.2011.180. Epub 2011 May 23. Oncogene. 2011. PMID: 21602893 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous